Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Leukemia, Myelomonocytic, Acute

ClinicalTrials.gov lists 187 trials for Leukemia, Myelomonocytic, Acute or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 51.

MeSH D015479 Neoplasms Neoplasm C04 C15
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 54 Phase 1/2 Phase 1/2 10 Phase 2 Phase 2 74 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 23 Phase 4 Phase 4 1 Not applicable Not applicable 5 Observational Observational 16 Phase 1 Phase 1 54 Phase 1/2 Phase 1/2 10 Phase 2 Phase 2 74 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 23 Phase 4 Phase 4 1 Not applicable Not applicable 5 Observational Observational 16

Trials per phase (log scale)

1 more section with rows

187 of the 187 trials are tagged with Leukemia, Myelomonocytic, Acute itself; the rest are tagged with a narrower condition beneath it.

Get the Leukemia, Myelomonocytic, Acute report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Leukemia, Myelomonocytic, Acute trials start? (27)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 18

1993: 1 trials (Phase 3 1) 1994: 4 trials (Phase 3 1, Phase 2 2, Phase 1 1) 1995: 1 trials (Phase 3 1) 1996: 2 trials (Phase 3 1, Phase 2 1) 1997: 1 trials (Phase 1/2 1) 1998: 9 trials (Phase 4 1, Phase 3 3, Phase 2 2, Phase 1 3) 1999: 8 trials (Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 2) 2000: 9 trials (Phase 3 3, Phase 2 6) 2001: 3 trials (Phase 2 3) 2002: 5 trials (Observational 1, Phase 3 2, Phase 2 1, Phase 1 1) 2003: 3 trials (Phase 2 1, Phase 1 2) 2004: 16 trials (Phase 3 2, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 6) 2005: 16 trials (Phase 3 3, Phase 2 1, Phase 1/2 1, Phase 1 11) 2006: 17 trials (Observational 3, Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 8, Phase 1 3) 2007: 8 trials (Other 1, Phase 2 2, Phase 1/2 2, Phase 1 3) 2008: 18 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 10, Phase 1/2 2, Phase 1 2) 2009: 5 trials (Observational 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2010: 15 trials (Observational 2, Phase 2 6, Phase 1 7) 2011: 16 trials (Observational 5, Phase 3 2, Phase 2 7, Phase 1/2 1, Phase 1 1) 2012: 5 trials (Observational 2, Phase 2 1, Phase 1 2) 2013: 8 trials (Not applicable 2, Phase 2 3, Phase 1 3) 2014: 7 trials (Not applicable 1, Phase 2 4, Phase 1 2) 2015: 1 trials (Phase 1 1) 2016: 1 trials (Phase 1 1) 2021: 3 trials (Phase 2 1, Phase 1 2) 2022: 1 trials (Phase 3 1) 2024: 1 trials (Phase 2/3 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2024 1
2022 1
2021 3
2016 1
2015 1
2014 7
2013 8
2012 5
2011 16
2010 15

Showing 10 of 27 earlier years.

Start your 14-day trial Email me all 27 earlier years as a PDF

No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Leukemia, Myelomonocytic, Acute trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 54
Phase 1/2 10
Phase 2 74
Phase 2/3 3
Phase 3 23
Phase 4 1
Not applicable 5
Observational 16
Expanded access 1

How many Leukemia, Myelomonocytic, Acute trials are recruiting? (7)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Recruiting 2
Active, not recruiting 5
Completed 134
Terminated 24
Withdrawn 4

Showing 5 of 7 statuses.

Start your 14-day trial Email me all 7 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Leukemia, Myelomonocytic, Acute trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 51
SWOG Cancer Research Network 11
European Organisation for Research and Treatment of Cancer - EORTC 8
Eastern Cooperative Oncology Group 6
Children's Oncology Group 5

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Leukemia, Myelomonocytic, Acute? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Mitoxantrone 22
Busulfan 18
Cytoxan 14
Tipifarnib 11
CLOFARABINE 10

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Cytarabine IT 82
Etoposid 31
Daunorubicine 30
Idarubicina 26
Filgrastime (G-CSF) 25

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Leukemia, Myelomonocytic, Acute trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Platelet count decreased 1,577 11
Neutrophil count decreased 1,531 13
Anemia 1,450 9
White blood cell decreased 1,234 8
Febrile neutropenia 983 22

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Leukemia, Myelomonocytic, Acute? (21)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Yes
Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2012 Yes
Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer research 2011 Yes
Anthracycline dose intensification in acute myeloid leukemia. The New England journal of medicine 2009 Yes
High-dose daunorubicin in older patients with acute myeloid leukemia. The New England journal of medicine 2009 Yes

Showing 5 of 21 publications.

Start your 14-day trial Email me all 21 publications as a PDF

Prevalence (4)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Acute myelomonocytic leukemia Annual incidence 1-9 / 1 000 000 Europe Not stated Exact
Acute myelomonocytic leukemia Point prevalence 1-9 / 1 000 000 Europe Not stated Exact
Acute myelomonocytic leukemia Point prevalence 1-9 / 1 000 000 Europe Not stated Exact
Acute myelomonocytic leukemia Annual incidence 1-9 / 1 000 000 Europe Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Acute myelomonocytic leukemia 517 Exact Orphanet Rare Disease Ontology (ORDO)
Acute myelomonocytic leukemia 517 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages